Mercator Therapeutics and Pepscan Therapeutics sign research and licensing collaboration


Lelystad/Waltham – Dutch Pepscan Therapeutics NV has licensed its protein technology CLIPS to US-based in vivo phage display specialist Mercator Therapeutics. Under the term of the agreement, Pepscan will use its platform to optimize Mercator’s “Homing peptides”, peptide drugs that have been demonstrated in vivo to bind to receptors that are overexpressed on human tumours and induce internalization of both the peptide and the receptor. Pepscan’s CLIPS technology makes use of native or newly introduced cysteines in the amino acid sequence of the peptides of interest to make single, double or triple bridges to lock them into their biologically active conformation and to improve the drug candidates' stability. Pepscan will receive research funding, milestones, and royalties in connection with the development of multiple optimized Homing Peptides and the development and commercialization of PDC products that couple optimized Homing Peptides with tumour-killing payloads. Further financial details were not disclosed.



Brussels – Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m. The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms...



Leuven – Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S. ThromboGenics said it...



Amsterdam Molecular Therapeutics has announced a financial manoeuvre aimed at getting the biotech out of a hopeless situation. The assets and – more importantly – the liabilities of the drug developer will be acquired by a newly...



Amsterdam - Amsterdam Molecular Therapeutics has announced a financial manoeuvre which is aimed to get the biotech out of a dead end. The assets and – more importantly – the liabilities of the drug developer will be acquired by...



Glasgow/Leuven - With a little help from the EU, two biotech companies are banding together to develop the first stem cell therapy against rheumatoid arthritis. UK-based Sistemic will work with TiGenix to develop the Belgian's...



Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM...



Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from...



Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered into a financing of approximately €8.4 million by...



Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a...

Displaying results 1 to 10 out of 304

1-10 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues